Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00576056 · ClinicalTrials.gov registry record · Phase 2
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
A Phase 2 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00576056 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 19 participants.
The verdict
NCT00576056, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.
Interventions
- DRUG Sorafenib
- DRUG TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00576056
The ClinicalTrials.gov registry entry for NCT00576056 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00576056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00576056 about?
NCT00576056 is a clinical study titled "Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC". The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.
What is the current status of trial NCT00576056?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2008-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00576056?
The interventions under investigation include: Sorafenib (DRUG), TACE (DRUG).
Who is sponsoring clinical trial NCT00576056?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.